⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PRAX News
Praxis Precision Medicines, Inc. Common Stock
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
PRAX
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
globenewswire.com
PRAX
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
globenewswire.com
PRAX
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
globenewswire.com
PRAX
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
globenewswire.com
PRAX
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
globenewswire.com
PRAX
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
globenewswire.com
PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
PRAX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
prnewswire.com
PRAX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
prnewswire.com
PRAX